Amphetamine-Antagonistic Property of 4-Phenyltetrahydroisoquinoline: Effect on Noradrenaline Release in Spinal Cord Slices

Mitsutoshi Satoh¹, Shigeru Ohta², Taku Nagao¹, Masaaki Hirobe², Hideomi Fukuda³ and Hideki Ono¹*¹

¹Department of Toxicology and Pharmacology, ²Department of Bioorganic and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Tokyo, Tokyo 113, Japan
³Department of Pharmacology, College of Pharmacy, Nihon University, Chiba 274, Japan

Received June 4, 1992 Accepted July 23, 1992

ABSTRACT—The amphetamine-related compounds methamphetamine, phenylethylamine and nomifensine increased the K⁺-evoked release of endogenous noradrenaline from rat spinal cord slices. 4-Phenyl-1,2,3,4-tetrahydroisoquinoline (4PTIQ), which alone did not affect the K⁺-evoked release of noradrenaline, inhibited the noradrenaline-releasing effects of methamphetamine, phenylethylamine and nomifensine. 4PTIQ revealed a weak noradrenaline-uptake inhibitory effect, and the effect was weaker than those of desipramine and nomifensine. These results showed that 4PTIQ is an antagonist against the amine-releasing effects of amphetamines.

Keywords: 4-Phenyl-1,2,3,4-tetrahydroisoquinoline, Methamphetamine, Noradrenaline release, Spinal cord

The CNS-stimulant actions of amphetamines are considered to be due to their ability to release monoamines from monoaminergic nerve terminals (1, 2), inhibition of monoamine uptake (3) and inhibition of monoamine oxidase (MAO) (4). However, the mechanism of the CNS-stimulating action of amphetamines, especially their monoamine-releasing effect, is still unclear. The most widely accepted hypothesis is that amphetamine increases amine efflux by accelerated exchange diffusion (5, 6). By recording the spinal monosynaptic reflex (MSR) of spinalized rats, we have found that amphetamine-related compounds, methamphetamine, phenylethylamine and nomifensine (8-amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline), increase the amplitude of the MSR by releasing noradrenaline from the noradrenergic terminals of descending fibers (7–10), and have suggested that 4-phenyl-1,2,3,4-tetrahydroisoquinoline (4PTIQ) antagonizes the effects of these compounds by inhibiting their noradrenaline-releasing effects (9).

In the present study, to further elucidate the inhibitory effects of 4PTIQ on noradrenaline release, we studied effects of 4PTIQ on the release of endogenous noradrenaline in rat spinal cord slices. The amphetamine-related compounds methamphetamine, phenylethylamine and nomifensine facilitated the K⁺-evoked release of noradrenaline, and 4PTIQ inhibited the stimulatory effects of amphetamines on the release. The blocking effects of 4PTIQ and other compounds on the noradrenaline uptake were also evaluated.

MATERIALS AND METHODS

Perfusion of rat spinal cord slices

Male Wistar rats, aged 9–10 weeks (b.wt. 250–330 g), were sacrificed by decapitation. The lumbar enlargement of the spinal cord (L4–L5) was rapidly removed. The tissue was chopped into 300- × 300-μm slices with a MacIlwain tissue chopper and then dispersed in Krebs-Ringer bicarbonate buffer of the following composition: 118 mM NaCl, 4.7 mM KCl, 1.3 mM CaCl₂, 1.2 mM MgCl₂, 1.0 mM NaH₂PO₄, 25 mM NaHCO₃, 11.1 mM glucose, 0.004 mM EDTA and 0.11 mM ascorbic acid. High K⁺ solution was made by replacing equimolar Na⁺. The medium, pH 7.4, was gassed throughout the experiment with 95% O₂–5% CO₂. Slices of about 50- to 60-mg wet tissue weight were placed in a perfusion chamber (0.5-ml internal volume) and perfused with the medium (37°C) for 60 min at a rate of 0.5 ml/min. A single 8-min (4-ml) sample was

*To whom correspondence should be addressed.
collected.

**Measurement of noradrenaline**

Noradrenaline in the perfusate was concentrated using alumina and determined by high performance liquid chromatography (HPLC) and electrochemical detection (ECD). The detection limit for noradrenaline was 50 fmol. Noradrenaline release was determined with 30 mM high K⁺ at 76 (S1) and 176 (S2) min after the start of perfusion. The release of noradrenaline evoked by high-K⁺ stimulation was estimated as described by Kamal et al. (2). Evoked release at the S1 and S2 periods of stimulation was estimated from the total amount minus basal release during stimulation. The test drugs were added to the perfusion medium 8 min before S2 and during stimulation, and their effects were evaluated in terms of the ratio of the amounts evoked in the S1 and S2 periods of stimulation (S2/S1).

**[^3H]Noradrenaline uptake**

The[^3H]noradrenaline uptake experiment was performed with synaptosomal fractions of rat spinal cord. The lumbar segment of the spinal cord was isolated, weighed and homogenized gently in 10 volumes of 0.32 M sucrose in a smooth glass homogenizer with a Teflon pestle (0.1 to 0.15-mm clearance). Following centrifugation of the homogenate at 4°C for 10 min at 1000 × g, the supernatant fraction was centrifuged at 12,000 × g for 30 min. The crude synaptosomal pellet (P2) was gently resuspended in 5–10 volumes of Krebs-Ringer bicarbonate buffer. Uptake of[^3H]noradrenaline was allowed to proceed for 5 min at 37°C, in 1 ml (final volume) of incubation medium that had been prewarmed for 10 min at 37°C prior to the addition of synaptosomes. The medium contained pargyline (10 μM) as a MAO inhibitor.[^3H]noradrenaline, 13.7 Ci/mmol, was diluted, and the final concentration of[^3H]noradrenaline was 35 nM. Following incubation at 0°C and 37°C for 5 min, the samples were diluted with 5 ml of chilled 50 mM Tris-HCl buffer (pH 7.4), filtered under vacuum on a Whatman GF/B manifold and then washed with a further 5 ml of buffer. Prior to filtration, the filters had been soaked with polyethyleneimine (0.1%) to lower the adsorption of[^3H]noradrenaline to the filters. Radioactivity on the filters was counted in 5 ml of Triton X-100 in toluene, containing 2,5-diphenyloxazole (PPO) and 1,4-dio[2-(5-phenyloxazolyl)]benzene (POPOP). All determinations were carried out in duplicate.

**Statistical analyses**

Numerical results are expressed as mean ± S.E., and Duncan’s New Multiple Range test was used to calculate statistical significance where appropriate. A P value less than 0.05 was considered to indicate a significant difference.

**Drugs**

Drugs used were (−)-noradrenaline hydrochloride (Alterenol, Sigma), pargyline hydrochloride (Sigma), 2-phenylethylamine hydrochloride (Tokyo Kasei), desipramine hydrochloride (Ciba-Geigy), S(+)-methamphetamine hydrochloride (Dainippon Seiyaku), nomifensine maleate (Hoechst), (−)[^3H]noradrenaline (specific activity, 13.7 Ci/mmol; New England Nuclear) and 4-phenyl-1,2,3,4-tetrahydroisoquinoline (4PTIQ) hydrochloride. 4PTIQ hydrochloride was synthesized (mp. of 217–219°C), and its purity was more than 99.7% by elemental analysis.

**RESULTS**

**Effects of amphetamine-related compounds on K⁺-evoked release of endogenous noradrenaline**

In the control experiment, the releases induced by 30 mM K⁺ from rat spinal cord slices, S1 and S2, were 1.41 ± 0.22 and 1.11 ± 0.23 pg/mg/min (n = 10), respectively. This high-K⁺-evoked release of endogenous noradrenaline was Ca²⁺-dependent.

Exposure of the spinal cord to methamphetamine (3 × 10⁻⁶ M), phenylethylamine (10⁻⁵ M) or nomifensine (10⁻⁵ M) increased the S2 (Figs. 1C and 2) without affecting the spontaneous outflow of noradrenaline. The ratio S2/S1 in the control experiment was not significantly different from unity. However, the S2/S1 ratios of methamphetamine (3 × 10⁻⁶ M), phenylethylamine (10⁻⁵ M) and nomifensine (10⁻⁵ M) were 2.39 ± 0.20, 2.62 ± 0.48 and 1.81 ± 0.31, respectively, being significantly different from that of the control (Figs. 1C and 2). Pargyline (10⁻⁵ M) and deprenyl (10⁻⁵ M), both MAO inhibitors, and desipramine (10⁻⁵ M), an uptake inhibitor, did not increase the S2/S1 ratio (Fig. 2). 4PTIQ (10⁻⁵ M) alone added 20 min before S2 did not affect the S2/S1 ratio (1.16 ± 0.15) (Fig. 2). 4PTIQ (10⁻⁵ M) added along with amphetamine-related compounds significantly reduced the S2/S1 ratios of methamphetamine (0.92 ± 0.11), phenylethylamine (1.18 ± 0.14) and nomifensine (0.85 ± 0.06) (Figs. 1D and 2).

**Effects of amphetamine-related compounds on[^3H]noradrenaline uptake into rat spinal cord synaptosomes**

The inhibitory effects on[^3H]noradrenaline uptake were compared among desipramine, nomifensine, methamphetamine, phenylethylamine and 4PTIQ. The order of potency in inhibiting[^3H]noradrenaline uptake...
Amphetamine and Noradrenaline Release

Fig. 1. Effects of 4PTIQ and methamphetamine on \( K^+ \)-evoked release of endogenous noradrenaline and inhibitory effects of 4PTIQ on facilitation of \( K^+ \)-evoked noradrenaline release from rat spinal cord slices induced by methamphetamine. High \( K^+ \)-stimulation was performed by increasing the KCl concentration of the perfusion medium to 30 mM for 8 min at 76 (\( S_1 \)) and 176 (\( S_2 \)) min after the start of perfusion (short line). The efflux of endogenous noradrenaline was measured by HPLC with electrochemical detection. Ordinates represent the overflow of endogenous noradrenaline in the perfusate for each 8-min sample. Abscissae represent the time after the spinal cord slices had been placed in the perfusion chamber. Drugs were applied to the perfusion medium 8 min before \( S_2 \) on the abscissae (long line). A, Control; B, 10\(^{-5}\) M 4PTIQ; C, 3 \times 10\(^{-6}\) M methamphetamine; D, 10\(^{-5}\) M 4PTIQ + 3 \times 10\(^{-6}\) M methamphetamine. Each value represents the mean ± S.E.M. of 3 - 6 experiments. #: P < 0.05, corresponding column.

Fig. 2. Effects of various drugs on \( K^+ \)-evoked release of endogenous noradrenaline and inhibitory effects of 4PTIQ on facilitation of \( K^+ \)-evoked noradrenaline release from rat spinal cord slices induced by stimulants. High \( K^+ \)-stimulation was performed by increasing the KCl concentration of the perfusion medium to 30 mM for 8 min at 76 (\( S_1 \)) and 176 (\( S_2 \)) min after the start of perfusion (shown in Fig. 1). The ordinate represents ratios of noradrenaline released in the \( S_1 \) and \( S_2 \) periods of stimulation. CONT, control; PAR, 10\(^{-5}\) M pargyline; DEP, 10\(^{-5}\) M deprenyl; DES, 10\(^{-7}\) M desipramine; 10\(^{-5}\) M 4PTIQ; MAP, 3 \times 10\(^{-6}\) M methamphetamine; PEA, 10\(^{-5}\) M phenylethylamine; NOM, 10\(^{-5}\) M nomifensine. Each value represents the mean ± S.E.M. of 3 - 6 experiments. #: P < 0.05 vs. control. *: P < 0.05 vs. corresponding column.
was desipramine > nomifensine > phenylethylamine = methamphetamine > 4PTIQ (Table 1). 4PTIQ was thus less potent than the other compounds.

### DISCUSSION

Terminals of noradrenergic neurons in the ventral horns of the spinal cord originate in the brain stem, e.g., the locus ceruleus (11–13). Methamphetamine, phenylethylamine and nomifensine release noradrenaline from the terminals of noradrenergic descending fibers, and the released noradrenaline increases the excitability of motoneurons and spinal reflex potentials via alpha2-adrenoceptors (9, 14–16). On the basis of recordings made of spinal reflex potentials, we have suggested that 4PTIQ blocks the noradrenaline-releasing effects of methamphetamine, phenylethylamine and nomifensine, and consequently antagonizes the MSR-stimulating effects of amphetamines (9).

In the present study, methamphetamine, phenylethylamine and nomifensine enhanced the K+-evoked release of noradrenaline. However, pargyline and deprenyl, MAO inhibitors, and desipramine, an amine uptake inhibitor, did not affected the S2/S1 ratio of the K+-evoked noradrenaline release. These results suggest that effects other than inhibition of MAO and its uptake enhanced the release of noradrenaline. Stamford et al. (17) showed that uptake inhibitors stimulate the overflow of dopamine in the nucleus accumbens during electrical stimulation of the medial forebrain bundle, without blocking the reuptake of dopamine after cessation of stimulation. They concluded that some uptake blockers can directly increase the release of dopamine in a manner unrelated to uptake blockade. Some other studies have shown dissociation of the actions of uptake blockers on dopamine release and dopamine uptake (3, 18). The present results, showing that methamphetamine, phenylethylamine and nomifensine increased the K+-evoked release of noradrenaline, resemble these of Stamford et al. (17).

4PTIQ, which alone did not increase the release of noradrenaline, reduced the increase in the K+-evoked release of noradrenaline produced by amphetamines. Thus the present results directly demonstrated the inhibitory effects of 4PTIQ on the noradrenaline-releasing effects of amphetamines, and confirmed the results obtained in reflex experiments. Desipramine (10⁻⁶ M) added along with methamphetamine significantly did not affect the S2/S1 ratio of methamphetamine. This fundamentally supports the possibility that the inhibiting effect of 4PTIQ on the noradrenaline-releasing effects of methamphetamine is different from the noradrenaline uptake-blocking effects of uptake-blockers such as desipramine.

4PTIQ showed a weak inhibitory effect on noradrenaline uptake into spinal cord synaptosomes, and the effect was weaker than those of all the other compounds tested. Thus, the inhibitory effects of 4PTIQ on amphetamines may not be due to the uptake-blocking effects of this compound. In addition, 4PTIQ blocked the noradrenaline-releasing effect of nomifensine, which is a strong amine uptake inhibitor (19).

The present results showed that 4PTIQ antagonizes the noradrenaline-releasing effects of methamphetamine, phenylethylamine and nomifensine in spinal cord slices. Preliminary data obtained in a behavioral study showed that 4PTIQ (s.c or microinjected into the nucleus accumbens) inhibited the ambulation-stimulating effect and dopamine-releasing effects of methamphetamine measured by the microdialysis method. Thus, 4PTIQ is considered to be a compound which has antagonistic effects against amphetamines and may be a useful tool for elucidating the monoamine-releasing mechanism of amphetamines.

### Acknowledgments

This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan. We are grateful to Hoechst for supplying nomifensine maleate.

### REFERENCES

1. Azzard, A.J. and Rutledge, C.O.: Selectivity of release of norepinephrine, dopamine and 5-hydroxytryptamine by amphetamine in various regions of rat brain. Biochem. Pharmacol. 22, 2801–2813 (1973)
2. Kamal, L.A., Arbilla, S. and Langer, S.Z.: Presynaptic mod-
lation of the release of dopamine from the rabbit caudate nucleus: Differences between electrical stimulation, amphetamine and tyramine. J. Pharmacol. Exp. Ther. 214, 592–598 (1981)
3 Bonnet, J.J., Lemasson, M.H. and Costentin, J.: Simultaneous evaluation by a double labelling method of drug-induced uptake inhibition and release of dopamine in synaptosomal preparation of rat striatum. Biochem. Pharmacol. 33, 2129–2135 (1984)
4 Green, A.L. and El Hait, M.A.S.: Inhibition of mouse brain monoamine oxidase by (+)-amphetamine in vivo. J. Pharm. Pharmacol. 30, 262–263 (1978)
5 Stein, W.D.: The Movement of Molecules Across Cell Membranes. p. 129–157, Academic Press, New York (1967)
6 Bönisch, H. and Trenderenburg, U.: The mechanism of action of indirectly acting sympathomimetic amines. In Handbook of Experimental Pharmacology, Vol. 90/I, Catecholamines I, Edited by Trendelenburg, U. and Weiner, N., p. 247–277, Springer-Verlag, Berlin (1988)
7 Hasebe, Y., Ono, H., Fukuda, H., Ohta, S. and Hirobe, M.: Enhancement of spinal reflexes with phenylethylamine and related drugs through descending noradrenergic neurons. J. Pharmacobiodyn. 12, 241–245 (1989)
8 Hasebe, Y., Ono, H., Fukuda, H., Ohta, S. and Hirobe, M.: The most desirable conformation of phenylethylamine (PEA) moiety stimulating noradrenergic neurons: Effects of PEA, methamphetamine, phenelzine, methylenephidate, nomifensine and mazindol on rat spinal reflexes. Gen. Pharmacol. 20, 375–379 (1989)
9 Ono, H., Hasebe, Y., Satoh, M., Nago, T., Ohta, S., Hirobe, M. and Fukuda, H.: Amphetamine-antagonistic properties of 4-phenyl-1,2,3,4-tetrahydroisoquinoline: Inhibition of spinal reflex-enhancing effects of methamphetamine, phenylethylamine and nomifensine. Brain Res. 564, 319–322 (1991)
10 Ono, H., Ito, H. and Fukuda, H.: 2-Phenylethylamine and methamphetamine enhance the spinal monosynaptic reflex by releasing noradrenaline from the terminals of descending fibers. Japan. J. Pharmacol. 55, 359–366 (1991)
11 Bjorklund, A. and Skagerberg, G.: Descending monoaminergic projections to the spinal cord. In Brain Stem Control of Spinal Mechanisms, Edited by Sjolund, B. and Bjorklund, A., p. 55–88, Elsevier Biomedical Press, Amsterdam (1982)
12 Strahlendorf, J.C., Strahlendorf, H.K., Kingsley, R.E., Gintautas, J. and Barnes, C.D.: Facilitation of the lumbar monosynaptic reflexes by locus coeruleus stimulation. Neuropharmacology 19, 225–230 (1980)
13 Westlund, K.N., Bowker, R.M., Ziegler, M.G. and Coulter, J.D.: Noradrenergic projections to the spinal cord of the rat. Brain Res. 263, 15–31 (1983)
14 Hirayama, T., Ono, H. and Fukuda, H.: Effects of adrenergic agents on ventral horn cells in rat spinal cord slices. Biomed. Res. 9, 343–351 (1988)
15 Hirayama, T., Ono, H. and Fukuda, H.: Functional supersensitivity of α-adrenergic system in spinal ventral horn is due to absence of an uptake system and not to postsynaptic change. Brain Res. 539, 320–323 (1991)
16 Ono, H., Hasebe, Y., Satoh, M., Nagao, T., Ohta, S., Hirobe, M. and Fukuda, H.: 4-Phenyl-1,2,3,4-tetrahydroisoquinoline: A candidate for an antagonist to noradrenaline-releasing effects of amphetamines. Eur. J. Pharmacol. 183, 447 (1990)
17 Stamford, J.A., Kruk, Z.L. and Millar, J.: Dissociation of actions of uptake blockers upon dopamine overflow and uptake in the rat nucleus accumbens: In vivo voltammetric data. Neuropharmacology 28, 1383–1388 (1989)
18 Heikkila, R.E., Orriansky, H. and Cohen, G.: Studies on the distinction between uptake inhibition and release of [3H]-dopamine in rat brain tissue slices. Biochem. Pharmacol. 24, 847–852 (1975)
19 Parker, E.M. and Cubeddu, L.X.: Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding. J. Pharmacol. Exp. Ther. 245, 199–210 (1988)